Publications by authors named "Andrew P Catchpole"

Claim this Profile
H
Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine.
Kelly A Lindert, Alex Mann, Anita Geevarughese, Teresa Hauguel, Sarah Mirza, Andrew P Catchpole

NEJM Evid· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems.
Nadine Rouphael, Ralph Tanios, Jessica Traenkner, Matthew D Pauly, Nishit Shetty, Andrew P Catchpole

J Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction for Shetty et al., "Influenza virus infection and aerosol shedding kinetics in a controlled human infection model".
Nishit Shetty, Meredith J Shephard, Nicole C Rockey, Hollie Macenczak, Jessica Traenkner, Andrew P Catchpole

J Virol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective Aerosol Inoculation of Dose-Escalated Seasonal Influenza H3N2 Virus in Controlled Human Infection Model.
Nadine Rouphael, Ralph Tanios, Jessica Traenkner, Matthew D Pauly, Nishit Shetty, Andrew P Catchpole

medRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus.
Mickie H Cheng, Alex J Mann, Brian M Maas, Tian Zhao, Melissa Bevan, Andrew P Catchpole

Pulm Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus.
Mickie H Cheng, Alex J Mann, Brian M Maas, Tian Zhao, Melissa Bevan, Andrew P Catchpole

Pulm Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in memory and cognition during the SARS-CoV-2 human challenge study.
William Trender, Peter J Hellyer, Ben Killingley, Mariya Kalinova, Alex J Mann, Andrew P Catchpole

EClinicalMedicine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults.
Jia Yao Phuah, Brian M Maas, Aimin Tang, Ying Zhang, Luzelena Caro, Andrew P Catchpole

Biomed Pharmacother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study.
Jie Zhou, Anika Singanayagam, Niluka Goonawardane, Maya Moshe, Fiachra P Sweeney, Andrew P Catchpole

Lancet Microbe· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic.
Maria Piggin, Emma Smith, Peter Mankone, Leah Ndegwa, Diane Gbesemete, Andrew P Catchpole

Epidemics· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.
Ben Killingley, Alex J Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Andrew P Catchpole

Nat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
Brian M Maas, Jos Lommerse, Nele Plock, Radha A Railkar, S Y Amy Cheung, Andrew P Catchpole

EBioMedicine· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process.
Andrew P Catchpole, Daniel J Fullen, Nicolas Noulin, Alex Mann, Anthony S Gilbert

BMC Res Notes· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis